Article: Emerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEmerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome
AuthorsJang, Y4
Lee, JH3
Wang, Y2
Sweeney, G1 5
Issue Date2012
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEP
CitationClinical and Experimental Pharmacology & Physiology, 2012, v. 39 n. 2, p. 194-199 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1681.2011.05557.x
AbstractThe inflammatory state, which is associated with the current pandemic of obesity, has been established as an important contributing pathogenic factor to the increased prevalence of the so-called metabolic syndrome. Many studies have focused on the contribution of various adipokines to this phenomenon, and in the present study, we provide an update on the emerging evidence that the pro-inflammatory factor, lipocalin-2, might influence various aspects of metabolic syndrome. Previous reports indicate a positive correlation of serum lipocalin-2 with fasting glucose, the homeostasis model assessment of insulin resistance index, and the inflammatory marker high-sensitivity C-reactive protein, even after adjustment for body mass index, suggesting that it is an independent risk factor for insulin resistance, diabetes, and inflammation. Direct analysis of lipocalin-2 action now also shows effects on peripheral metabolism and on cardiovascular function. A better understanding of how lipocalin-2 is regulated locally and systemically is crucial for adding to our understanding of the pathogenesis of metabolic syndrome, and to uncover potential new avenues for therapeutic approaches.
ISSN0305-1870
2011 Impact Factor: 1.851
2011 SCImago Journal Rankings: 0.155
DOIhttp://dx.doi.org/10.1111/j.1440-1681.2011.05557.x
DC Field
Value
dc.contributor.authorJang, Y
dc.contributor.authorLee, JH
dc.contributor.authorWang, Y
dc.contributor.authorSweeney, G
dc.date.accessioned2011-09-23T05:52:28Z
dc.date.available2011-09-23T05:52:28Z
dc.date.issued2012
dc.description.abstractThe inflammatory state, which is associated with the current pandemic of obesity, has been established as an important contributing pathogenic factor to the increased prevalence of the so-called metabolic syndrome. Many studies have focused on the contribution of various adipokines to this phenomenon, and in the present study, we provide an update on the emerging evidence that the pro-inflammatory factor, lipocalin-2, might influence various aspects of metabolic syndrome. Previous reports indicate a positive correlation of serum lipocalin-2 with fasting glucose, the homeostasis model assessment of insulin resistance index, and the inflammatory marker high-sensitivity C-reactive protein, even after adjustment for body mass index, suggesting that it is an independent risk factor for insulin resistance, diabetes, and inflammation. Direct analysis of lipocalin-2 action now also shows effects on peripheral metabolism and on cardiovascular function. A better understanding of how lipocalin-2 is regulated locally and systemically is crucial for adding to our understanding of the pathogenesis of metabolic syndrome, and to uncover potential new avenues for therapeutic approaches.
dc.description.naturelink_to_OA_fulltext
dc.identifier.citationClinical and Experimental Pharmacology & Physiology, 2012, v. 39 n. 2, p. 194-199 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1440-1681.2011.05557.x
dc.identifier.doihttp://dx.doi.org/10.1111/j.1440-1681.2011.05557.x
dc.identifier.epage199
dc.identifier.hkuros195689
dc.identifier.issn0305-1870
2011 Impact Factor: 1.851
2011 SCImago Journal Rankings: 0.155
dc.identifier.issue2
dc.identifier.pmid21689137
dc.identifier.scopuseid_2-s2.0-84863030946
dc.identifier.spage194
dc.identifier.urihttp://hdl.handle.net/10722/139606
dc.identifier.volume39
dc.languageeng
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEP
dc.publisher.placeAustralia
dc.relation.ispartofClinical and Experimental Pharmacology & Physiology
dc.rightsThe definitive version is available at www.blackwell-synergy.com
dc.subject.meshAcute-Phase Proteins - physiology
dc.subject.meshLipocalins - physiology
dc.subject.meshMetabolic Syndrome X - metabolism - therapy
dc.subject.meshObesity - metabolism - therapy
dc.subject.meshProto-Oncogene Proteins - physiology
dc.titleEmerging clinical and experimental evidence for the role of lipocalin-2 in metabolic syndrome
dc.typeArticle
Author Affiliations
  1. York Universite Canada
  2. The University of Hong Kong
  3. Yonsei University
  4. Yonsei University College of Medicine
  5. Institut Pasteur Korea